Alkem Laboratories Share Price in Focus as CFO Nitin Agrawal Announces Resignation

On September 24, 2026, Alkem Laboratories Limited formally announced a change in its key managerial personnel with the resignation of Chief Financial Officer Nitin Agrawal, as per the exchange filings.  

Details of the CFO Resignation 

Nitin Agrawal, the Chief Financial Officer and Key Managerial Personnel of Alkem Laboratories, has tendered his resignation to explore new professional and personal growth opportunities.  

His resignation was initially submitted to the Chairman on July 30, 2026, and will take effect at the close of business on September 30, 2026. 

Strategic Contributions by Nitin Agrawal 

During his tenure, Agrawal led several strategic initiatives, including the establishment of the MedTech vertical and the acquisition of companies such as Adroit, Bombay Ortho, Alkem Wellness, and Occlutech.  

He also managed international expansions, including setting up a joint venture in Saudi Arabia, and was instrumental in the liquidation of idle assets, enhancing treasury returns, and implementing UCPMP marketing guidelines. 

Transition and Continuity Plan 

Agrawal expressed gratitude to the Board of Directors for their support during his service. He remains committed to assisting the company through the transition, ensuring a seamless handover of ongoing projects until his departure. 

Read More: Skipper Share Price Gains as It Secures ₹797 Crore Orders in Power Transmission Sector! 

Alkem Laboratories Share Price Performance 

As of September 24, 2026, at 1:34 PM, Alkem Laboratories share price on NSE was trading at ₹5,337.00, down by 1.49% from the previous closing price. 

Conclusion 

Alkem Laboratories has announced the resignation of CFO Nitin Agrawal, effective September 30, 2026. Agrawal contributed to strategic mandates, acquisitions, and international expansions, and will assist in the transition process until his departure. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.